» Articles » PMID: 27485076

Use of LDH and Autoimmune Side Effects to Predict Response to Ipilimumab Treatment

Overview
Journal Immunotherapy
Date 2016 Aug 4
PMID 27485076
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation.

Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data.

Results: A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit.

Conclusion: Changes in LDH level and side effects correlate with response to therapy and survival.

Citing Articles

Mediation effect of stroke recurrence in the association between post-stroke lactate dehydrogenase and functional disability.

He Q, Wang M, Zhu H, Xiao Y, Wen R, Liu X Front Aging Neurosci. 2024; 16:1450863.

PMID: 39280700 PMC: 11392875. DOI: 10.3389/fnagi.2024.1450863.


Young patients show poor efficacy for immune checkpoint inhibitor combined therapy in metastatic gastrointestinal cancers.

Wang Y, Zhang S, Zhang F, Wang L, Wu C, Zhang X Front Oncol. 2023; 13:1155019.

PMID: 37207161 PMC: 10189879. DOI: 10.3389/fonc.2023.1155019.


Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy.

Tomela K, Pietrzak B, Galus L, Mackiewicz J, Schmidt M, Mackiewicz A Cells. 2023; 12(5).

PMID: 36899926 PMC: 10000540. DOI: 10.3390/cells12050789.


Lactate dehydrogenase/albumin ratio as a prognostic factor in severe acute respiratory distress syndrome cases associated with COVID-19.

Sipahioglu H, Onuk S Medicine (Baltimore). 2022; 101(38):e30759.

PMID: 36197158 PMC: 9508955. DOI: 10.1097/MD.0000000000030759.


Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.

Sun Q, Sun H, Wu N, Hu Y, Zhang F, Cong X Front Oncol. 2022; 12:976224.

PMID: 36185176 PMC: 9515964. DOI: 10.3389/fonc.2022.976224.